Tabloid Related Published Studies
Well-designed clinical trials related to Tabloid (Thioguanine)
6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. [2007.07]
6-Thioguanine Nucleotide-Adapted Azathioprine Therapy Does Not Lead to Higher Remission Rates Than Standard Therapy in Chronic Active Crohn Disease: Results from a Randomized, Controlled, Open Trial. [2007.05.10]
Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. [2006.10.14]
The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia. [2006.10]
Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy. [2005.03]
Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle. [2004.01]
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. [2003.12.15]
High-performance liquid chromatographic assay of metabolites of thioguanine and mercaptopurine in capillary blood. [2003.10.25]
Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. [2003.10.15]
A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486). [2003.09]
Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. [2002.07]
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. [1999.06.15]
Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. [1998]
Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison. [1995.07]
Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group. [1994.01]
Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B. [1992.11]
Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Results from MRC CML. II. Trial comparing busulphan with busulphan and thioguanine. [1991.10]
Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results. [1989.02]
Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. [1989.02]
Well-designed clinical trials possibly related to Tabloid (Thioguanine)
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. [2008.01]
Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. [2007.12.20]
Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia. [2007.05]
Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. [2006.03]
Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. [2006.02.15]
Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. [2005.12]
Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. [2005.11.01]
Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci. [2005.03]
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. [2003.09]
High variation of tioguanine absorption in patients with chronic active Crohn's disease. [2003.07.15]
Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. [2003.06]
[Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93] [2003.05]
Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. [2003.04.01]
Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group. [2002.11]
Long-term follow-up of patients >or=60 yr old with acute myeloid leukaemia treated with intensive chemotherapy. [2002.06]
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. [2001.09.01]
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. [2001.09.01]
Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. [2001.04]
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. [2001.01]
Intravenous azathioprine in severe ulcerative colitis: a pilot study. [2000.12]
Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia. [2000.03]
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. [1999.09]
The accessibility of information systems for patients: use of touchscreen information systems by 345 patients with cancer in Scotland. [1999]
Improved survival with early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI. Medical Research Council Working Party on Childhood Leukaemia. [1998.07]
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. [1998.04]
Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. [1998.02.01]
Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. [1997.11]
Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. [1997.04.01]
Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. [1996.09]
Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party. [1996.07]
Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. [1996.06.15]
Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. [1996.05.30]
A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group. [1996.04.15]
Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial). [1995.09]
Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. [1995.06]
The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation: a report from the Childrens Cancer Group. [1993.12.01]
Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. [1993.06]
Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group. [1993.04]
[Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study] [1992.07]
[Effect of cranial irradiation on rate of recurrence in children with acute myeloid leukemia. Initial results of the AML-BFM-87 study. The AML-BFM Study Group] [1992.07]
Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study. [1992.06]
Varying intensity of postremission therapy in acute myeloid leukemia. [1992.04.15]
A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA. [1992.04]
Ceftazidime as initial therapy in febrile patients with acute leukemia during induction chemotherapy. Leukemia Group of Middle Sweden. [1992]
Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience. [1992]
Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG. [1992]
In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML). [1991.12]
A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. [1991.11.15]
Value of maintenance therapy with chemotherapy or interferon during remission of acute myeloid leukaemia. [1991.09]
Long-term outcome of adults with acute myelogenous leukaemia: results of a prospective, randomized study of chemotherapy with a minimal follow-up of 7 years. [1991.04]
A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study. [1991.02]
A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. [1991]
[Adult acute lymphoblastic leukemia: preliminary results of the LAL-86 protocol] [1990.02]
Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial. [1990]
Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial. [1990]
Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group. [1989.04.15]
Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. [1989.04]
Intensive maintenance therapy improves survival in adult acute nonlymphocytic leukemia: an eight-year follow-up. [1988.07]
Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. [1988.04]
Randomized multicentric Italian study on two treatment regimens for marrow relapse in childhood acute lymphoblastic leukemia. [1986]
Other research related to Tabloid (Thioguanine)
Studies of thioguanine-resistant lymphocytes induced by in vivo irradiation of mice. [2008.06]
Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. [2008.06]
Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. [2008.02]
6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. [2007.11]
Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942). [2007.09]
Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease. [2007.04]
Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease. [2007.02]
Extended thiopurine metabolite assessment during 6-thioguanine therapy for immunomodulation in Crohn's disease. [2007.02]
Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects? [2007.02]
A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. [2007]
HGPRT mutation induction by N-ethyl-N-nitrosourea as measured by 6-thioguanine resistance is higher in male than in female Syrian hamster fetuses. [2006.10]
Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases. [2006.06]
6-Thioguanine-related chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukaemia--a dual-centre experience. [2006.05]
5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. [2006.04]
Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. [2006.04]
Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia. [2006.02]
Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease. [2006.02]
6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. [2006]
6-Thioguanine for Crohn's disease during pregnancy: thiopurine metabolite measurements in both mother and child. [2005.11]
[Neutrophilic eccrine hidradenitis secondary to thioguanine in a neutropenic patient] [2005.11]
A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis. [2005.10]
Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. [2005.10]
|
